Manal F Abdelmalek
Overview
Explore the profile of Manal F Abdelmalek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
10236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takawy M, Abdelmalek M
Curr Diab Rep
. 2025 Feb;
25(1):23.
PMID: 39964660
Purpose Of Review: This review highlights the impact of weight loss on metabolic dysfunction associated steatotic liver disease (MASLD), formally known as nonalcoholic fatty liver disease (NAFLD), and its progressive...
2.
Coombes J, Manka P, Swiderska-Syn M, Vannan D, Riva A, Claridge L, et al.
Liver Int
. 2024 Oct;
45(4):e16131.
PMID: 39422353
Background And Aims: Osteopontin (OPN) promotes the ductular reaction and is a major driver of chronic liver disease (CLD) progression. Although CLD is characterised by the accumulation of inflammatory cells...
3.
Bae G, Dunleavy K, Hagen C, Simonetto D, Abdelmalek M
ACG Case Rep J
. 2024 Oct;
11(10):e01532.
PMID: 39391806
Hepatic angiosarcoma is a rare and aggressive liver tumor. We report a case study of an 82-year-old elderly gentleman who presented with failure to thrive and ascites. Initially suspected to...
4.
Schubach A, Carr R, Abdelmalek M
N Engl J Med
. 2024 Jul;
391(4):373-375.
PMID: 39047247
No abstract available.
5.
Cooreman M, Butler J, Giugliano R, Zannad F, Dzen L, Huot-Marchand P, et al.
Nat Commun
. 2024 May;
15(1):3962.
PMID: 38730247
Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial secondary...
6.
Abdelmalek M, Harrison S, Sanyal A
Diabetes Obes Metab
. 2024 Mar;
26(6):2001-2016.
PMID: 38511418
Despite its considerable and growing burden, there are currently no Food and Drug Administration-approved treatments for metabolic dysfunction-associated steatotic liver disease or its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). Several...
7.
Murphy W, Diehl A, Loop M, Fu D, Guy C, Abdelmalek M, et al.
Hepatol Commun
. 2024 Feb;
8(3).
PMID: 38381537
Background: NAFLD is highly prevalent with limited treatment options. Bile acids (BAs) increase in the systemic circulation and liver during NAFLD progression. Changes in plasma membrane localization and zonal distribution...
8.
Harrison S, Bedossa P, Guy C, Schattenberg J, Loomba R, Taub R, et al.
N Engl J Med
. 2024 Feb;
390(6):497-509.
PMID: 38324483
Background: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH...
9.
Francque S, Hodge A, Boursier J, Younes Z, Rodriguez-Araujo G, Park G, et al.
Hepatol Commun
. 2024 Jan;
8(2).
PMID: 38285756
Background: Cenicriviroc (CVC) is a novel, orally administered antagonist of chemokine receptor types 2/5 that has demonstrated antifibrotic activity in a phase 2b study of patients with NASH. This phase...
10.
Abdelmalek M, Rinella M
Hepatology
. 2023 Dec;
79(6):1252-1254.
PMID: 38100309
No abstract available.